MEDIPOST America
MEDIPOST is a global leader in stem cell therapeutics, dedicated to overcoming incurable diseases through regenerative medical care. The company focuses on innovative stem cell research, clinical trials, and the development of advanced biopharmaceuticals, including products like CARTISTEM®. With a strong emphasis on quality, safety, and global standards, MEDIPOST aims to create a new history in biotechnology by continuously challenging and innovating in the field of regenerative medicine.
Industries
Nr. of Employees
medium (51-250)
MEDIPOST America
Rockville, Maryland, United States, North America
Products
Allogeneic umbilical cord blood-derived mesenchymal stem cell therapy for knee cartilage defects
A surgically administered cell therapy using allogeneic umbilical cord blood-derived mesenchymal stem cells for treatment of severe knee cartilage defects and degenerative osteoarthritis.
Intra-articular injectable cell therapy for osteoarthritis
An intra-articular injectable cell-based therapeutic intended for treatment of knee osteoarthritis delivered via injection.
Intravenous cell therapy for diabetic nephropathy
An intravenously administered cell-based therapy developed for treatment of diabetic nephropathy.
Allogeneic umbilical cord blood-derived mesenchymal stem cell therapy for knee cartilage defects
A surgically administered cell therapy using allogeneic umbilical cord blood-derived mesenchymal stem cells for treatment of severe knee cartilage defects and degenerative osteoarthritis.
Intra-articular injectable cell therapy for osteoarthritis
An intra-articular injectable cell-based therapeutic intended for treatment of knee osteoarthritis delivered via injection.
Intravenous cell therapy for diabetic nephropathy
An intravenously administered cell-based therapy developed for treatment of diabetic nephropathy.
Services
End-to-end development and manufacturing services including process development, technology transfer, GMP manufacturing, quality testing, and licensing/regulatory support for cell and gene therapy products.
Microbial testing (mycoplasma, sterility), endotoxin assays, cell characterization (phenotyping, differentiation testing), ELISA cytokine/protein analysis, and viability testing provided to GMP standards.
Contract manufacturing for autologous/allogeneic cells, immune and gene-modified cell products, exosomes and related biologicals with capacity for multilayer culture, bioreactors, large centrifugation, filling and cryostorage.
Coordination with hospital partners to facilitate donation and supply of biological raw materials including cord blood, placenta, umbilical cord and peripheral blood.
Umbilical cord blood collection, processing, controlled-rate freezing and long-term cryostorage with release procedures for transplantation.
End-to-end development and manufacturing services including process development, technology transfer, GMP manufacturing, quality testing, and licensing/regulatory support for cell and gene therapy products.
Microbial testing (mycoplasma, sterility), endotoxin assays, cell characterization (phenotyping, differentiation testing), ELISA cytokine/protein analysis, and viability testing provided to GMP standards.
Contract manufacturing for autologous/allogeneic cells, immune and gene-modified cell products, exosomes and related biologicals with capacity for multilayer culture, bioreactors, large centrifugation, filling and cryostorage.
Coordination with hospital partners to facilitate donation and supply of biological raw materials including cord blood, placenta, umbilical cord and peripheral blood.
Umbilical cord blood collection, processing, controlled-rate freezing and long-term cryostorage with release procedures for transplantation.
Expertise Areas
- CDMO and contract manufacturing for cell and gene therapies
- Process development and MSAT for advanced biologics
- Biologics analytical testing and quality control
- Cryopreservation and cord blood biobanking
Key Technologies
- Flow cytometry
- Real-time PCR
- ELISA and enzyme immunoassays
- LAL kinetic turbidimetric endotoxin assay
News & Updates
MEDIPOST Recruits Local Experts to U.S. Subsidiary, Accelerating North American Launch of CARTISTEM®
MEDIPOST has recruited local experts to its U.S. subsidiary to accelerate the launch of CARTISTEM® in North America.
MEDIPOST has completed the administration of its phase 3 clinical trial for CARTISTEM® in Japan.
CARTISTEM® has reached a milestone of treating 30,000 patients worldwide.
Number of registered patents in Korea and overseas
Number of national R&D grants received in Korea
Number of private cord blood units stored
MEDIPOST Recruits Local Experts to U.S. Subsidiary, Accelerating North American Launch of CARTISTEM®
MEDIPOST has recruited local experts to its U.S. subsidiary to accelerate the launch of CARTISTEM® in North America.
MEDIPOST has completed the administration of its phase 3 clinical trial for CARTISTEM® in Japan.
CARTISTEM® has reached a milestone of treating 30,000 patients worldwide.